Obesity Drug Pipeline Timeline 2026

How Should Researchers Read This Timeline?

The most useful way to read the 2026 obesity pipeline is to separate four event types: approvals already won, pending FDA decisions, Phase 3 readouts that feed future filings, and post-approval launch checkpoints. That framing keeps this page focused on timing instead of duplicating the direct approval answers handled by the drug-specific status pages.

In practice, that means Foundayo now belongs in the post-approval bucket, CagriSema stays in the pending-decision bucket, and retatrutide remains in the readout-to-filing bucket until Lilly confirms a submission. Programs like survodutide, VK2735, and zenagamtide matter because they can change the next filing wave even without an immediate FDA action.

If you need the definitive regulatory answer for one drug, use the linked status page. If you need the sequence of what lands next, what reads out next, and what could move the pipeline next, this calendar is the better page.

Which 2026 Windows Matter Most?

The highest-signal regulatory window left in 2026 is CagriSema. After Novo Nordisk’s December 2025 filing, the key question is no longer whether the data set exists, but whether the FDA converts that package into the first approved amylin-plus-GLP-1 obesity product in late 2026.

The densest readout window belongs to retatrutide. Every positive TRIUMPH update increases confidence in Lilly’s future filing package, but each readout is still a catalyst rather than a final approval event. That is why this page tracks milestone sequencing while the retatrutide status page handles the yes-or-no question.

The third important window is the oral segment. Foundayo has already changed the answer on oral obesity drugs, so the remaining question is whether launch uptake, payer access, and later-wave programs like oral VK2735 can reshape the category by year-end.

Why Do Oral and Label-Expansion Dates Matter?

The oral timeline no longer starts with a hypothetical approval question. It now starts with two approved products: the Wegovy pill and Foundayo. That shifts the relevant 2026 events toward launch execution, access checkpoints, and the next datasets that could support broader label or geographic expansion.

That is also why oral VK2735 matters even before approval. Its job in the 2026 calendar is not to answer a status question; it is to show whether a later-wave oral dual agonist can build a competitive filing path against two already-approved oral GLP-1 products.

The same logic applies to comorbidity programs. Sleep apnea, MASH, osteoarthritis, HFpEF, and diabetes readouts are not side stories. They help determine how broad future labels can become, which is why they belong in the calendar even when they do not create an immediate obesity approval event.

What CagriSema Catalysts Are Expected in 2026?

CagriSema (cagrilintide + semaglutide) is the closest obesity drug to an FDA decision in 2026. Novo Nordisk filed the NDA in December 2025, placing the expected PDUFA date around October 2026. This is the single highest-impact regulatory catalyst of the year. For the current status of every pending submission, see our obesity drug approval tracker for 2026.

The filing is supported by the REDEFINE clinical program. The pivotal REDEFINE 1 trial showed 22.7% mean weight loss at 68 weeks, significantly exceeding the semaglutide-alone arm. CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide) in a single injection.

Beyond the FDA decision, the REDEFINE 6 trial (adolescent population, ages 12–17) is expected to read out in 2026. Positive adolescent data would expand the potential prescribing label significantly. Novo Nordisk has also disclosed plans for cardiovascular outcomes data from the REDEFINE program, though the timeline for those results extends beyond 2026.

What Retatrutide Data Is Coming in 2026?

Retatrutide is Eli Lilly’s triple agonist (GLP-1, GIP, and glucagon receptor agonist) and the most potent weight-loss drug in Phase 3 development. The TRIUMPH-4 trial reported topline results in August 2025 showing 28.7% mean body weight reduction at 68 weeks — the highest figure ever reported in a Phase 3 obesity trial. For a mechanistic deep dive, see our explainer on the triple agonist GIP, GLP-1, and glucagon pathway.

Seven additional TRIUMPH Phase 3 readouts are expected through 2026, making retatrutide the most data-rich pipeline asset this year:

TRIUMPH-1 (type 2 diabetes) — efficacy and safety in T2D patients. TRIUMPH-2 (weight maintenance) — whether weight loss is sustained after stepping down from the treatment dose. TRIUMPH-3 (obstructive sleep apnea) — an expanding-indications play following Zepbound’s OSA approval. TRIUMPH-5 (MASH/liver) — addressing metabolic liver disease. TRIUMPH-6 (HFpEF) — heart failure with preserved ejection fraction. TRIUMPH-7 (knee osteoarthritis) — a novel weight-related joint disease indication.

Eli Lilly has not confirmed an NDA filing date, but the breadth of the TRIUMPH program suggests a filing in late 2026 or early 2027. If filed in late 2026, an FDA decision would come no earlier than mid-to-late 2027. See our retatrutide vs tirzepatide vs CagriSema comparison for how these three leading candidates stack up.

What Is Next for Foundayo (Orforglipron) in 2026?

Orforglipron is no longer a future-approval story in obesity. Lilly’s oral non-peptide GLP-1 was FDA approved as Foundayo on April 1, 2026, making it the first oral GLP-1 for obesity that can be taken at any time of day without food or water restrictions. That changes the job of this page: the relevant 2026 events are now launch execution, broader access, and the next data packages that could support expansion.

The original obesity filing has already converted into approval, but additional company milestones still matter. Lilly continues to report broader oral-program data across obesity and type 2 diabetes, and those updates help define how aggressively Foundayo can extend beyond the initial launch phase.

Foundayo’s competitive case still rests on convenience: it is a once-daily pill with no food or water dosing restrictions, unlike the Wegovy pill, which requires fasting conditions. That means the 2026 calendar is really a launch-comparison timeline between two approved oral GLP-1 products plus the next investigational oral entrants.

For the direct regulatory answer, use the orforglipron status page. For the post-approval label, pricing, and market-impact view, use the Foundayo deep dive. For a broader oral segment comparison, see our oral obesity drugs 2026 guide.

Where Does Survodutide Stand in 2026?

Survodutide (Boehringer Ingelheim / Zealand Pharma) is a dual GLP-1/glucagon receptor agonist in the Phase 3 SYNCHRONIZE program. The program includes four trials: SYNCHRONIZE-1 (obesity), SYNCHRONIZE-2 (T2D), SYNCHRONIZE-3 (MASH), and SYNCHRONIZE-4.

No Phase 3 efficacy results have been reported yet. The Phase 2 data showed approximately 19% weight loss, which placed survodutide among the higher-efficacy investigational agents. The key question for 2026 is whether the SYNCHRONIZE program produces initial Phase 3 readouts by year-end or pushes into 2027.

Survodutide’s dual-agonist mechanism (GLP-1 + glucagon) differs from retatrutide’s triple-agonist approach and from CagriSema’s GLP-1/amylin combination, making it a structurally distinct competitive entry. Phase 2 data also showed liver-fat reduction, positioning it as a potential MASH therapy alongside its obesity indication. For help evaluating these candidates, see our analysis of the best obesity drug in 2026.

Mazdutide (IBI362): The Dual GLP-1/Glucagon Agonist

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics under license from Eli Lilly. It is not a triple agonist — unlike retatrutide, mazdutide omits GIP receptor engagement entirely, activating only two receptor targets (GLP-1R and GCGR). The compound received its first regulatory approval in China in 2025 for type 2 diabetes and is being evaluated for obesity under the Phase 3 GLORY program. Clinical data show approximately 11–15% mean weight reduction, placing it below the triple-agonist ceiling but confirming meaningful efficacy from the GLP-1 + glucagon combination alone.

Mazdutide’s scientific importance extends beyond its clinical results. Because it isolates GLP-1 + glucagon receptor activation without GIP, comparing mazdutide outcomes to retatrutide’s GLP-1 + GIP + glucagon results allows researchers to infer the approximate contribution of GIP receptor agonism to metabolic outcomes. This makes mazdutide a critical reference compound for understanding why triple agonists achieve higher weight loss than dual agonists. Results from the GLORY program in China could arrive in 2026, though the regulatory pathway is distinct from the US/EU process. For the full compound profile and comparison, see the mazdutide section above.

What Other Obesity Drugs Have 2026 Milestones?

Wegovy pill (oral semaglutide 25 mg). FDA approved in late 2025, the Wegovy pill is the first oral GLP-1 drug indicated for obesity, building on the Rybelsus oral semaglutide platform originally approved for diabetes. Commercial launch is ramping through early-to-mid 2026. Real-world uptake data will be a key milestone. OASIS 4 showed 16.6% mean weight loss.

Amycretin / Zenagamtide (Novo Nordisk). This unimolecular GLP-1/amylin agonist is in Phase 2. Results are expected in 2026 and will determine whether Novo Nordisk advances amycretin into Phase 3. Early Phase 1 data showed rapid weight loss over short treatment periods, generating significant anticipation.

VK2735 (Viking Therapeutics). The subcutaneous formulation is in Phase 3 (VANQUISH trial, enrolling). The oral formulation showed 12.2% weight loss at just 13 weeks in Phase 2 (VENTURE-Oral), the fastest rate of any oral agent in development. Oral Phase 3 is expected to start in 2026–2027.

Petrelintide (Roche / Zealand Pharma). This amylin analog reported 10.7% weight loss at 42 weeks in the Phase 2 ZUPREME-1 trial. Roche is evaluating whether to advance to Phase 3. A decision is expected in 2026.

Mazdutide (Innovent / Eli Lilly China). A dual GLP-1/glucagon agonist in the GLORY Phase 3 program in China. Results from the Chinese trials could come in 2026, though the regulatory pathway is distinct from the US/EU process.